| ¿µ¹® | chronic lymphocytic leukemia | ÇÑ±Û | ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´ |
|---|---|---|---|
| ¼³¸í | ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀÎ »óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐȼ¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀÎ ÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀÎ ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ ã¾Æ¿À°Ô µÈ´Ù. µû¶ó¼ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇÏ´Â °ñ¼ö Á¶Á÷¿¡¼´Â ÀÌ·± ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù. ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼¾ç¿¡¼´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼´Â °ÅÀÇ Ã£¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ¸ç ´ë°³ Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ ÈÇпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù. |
||
| ¿µ¹® | leukemia | ÇÑ±Û | ¹éÇ÷º´ |
|---|---|---|---|
| ¼³¸í | ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀÎ »óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊ Ç÷¾×¿¡ ¹ÌºÐȼ¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀÎ ÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀÎ ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ ã¾Æ¿À°Ô µÈ´Ù. µû¶ó¼ ÀûÇ÷±¸ ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ£ ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇÏ´Â °ñ¼ö Á¶Á÷¿¡¼´Â ÀÌ·± ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù. ÀÌ·± ¹éÇ÷º´¿¡´Â ¿©·¯ °¡Áö°¡ ÀÖ´Â µ¥ Å©°Ô 4°¡Áö·Î ³ª´©¾î ºÐ·ùÇÑ´Ù. Á¤»óÀûÀ¸·Î ¹éÇ÷±¸¼¼Æ÷´Â ¸²ÇÁ°è¼¼Æ÷¿Í °ñ¼ö°è¼¼Æ÷·Î 2ºÐµÇ´Âµ¥, ¹éÇ÷º´ ¶ÇÇÑ ÀÌ·± ¸²ÇÁ°è¼¼Æ÷ÀÇ Áõ½Ä°ú °ñ¼ö°è¼¼Æ÷ÀÇ Áõ½Ä¿¡ µû¶ó ³ª´©¸ç, ±× Áõ»óÀÌ ¾ó¸¶³ª »¡¸® ³ªÅ¸³ª´Â °¡¿¡ µû¶ó ¸¸¼º, ±Þ¼ºÀ¸·Î ³ª´«´Ù. µû¶ó¼ ¿©±â¿¡´Â ´ÙÀ½ 4°¡ÁöÀÇ ºÐ·ù°¡ ³ª¿À°Ô µÈ´Ù. -±Þ¼º¸²ÇÁ¼º ¹éÇ÷º´: acute lymphocytic -±Þ¼º°ñ¼ö¼º ¹éÇ÷º´: acute myelogenous -¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´: chronic lymphocytic -¸¸¼º°ñ¼ö¼º ¹éÇ÷º´: chronic myelogenous. |
||
| AML | Acute Myelogenous Leukemia Morphologic Classification(FABºÐ·ù) &n... |
|---|---|
| AML | acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem... |
| CML | carboxymethyl lysine; cell-mediated lymphocytotoxicity; cell-mediated lympholysis; central motor lat... |
| CML | Chronic Myelogenous Leukemia * Lymphoid Blastic Crisis(- 1/3)½Ã Ä¡·á´Â ALL¿¡ ÁØÇؼ  ... |
| JCML | juvenile chronic myelogenous leukemia |
| M2 | myelogenous leukemia |
|---|---|
| AML | Acute Myelogenous Leukaemia |
| CML | Chronic Myelogenous Leukaemia |
| JCML | Juvenile chronic myelogenous leukaemia |
| CGL | 9--chronic granulocytic leukemia |
acute monocytic leukemia
| leukemia | <haematology> An acute or chronic disease of unknown cause in man and other warm blooded animals that involves the blood forming organs, is characterised by an abnormal increase in the number of leucocytes in the tissues of the body with or without a corresponding increase of those in the circulating blood and is classified according of the type leucocyte most prominently involved. (18 Nov 1997) |
|---|---|
| acute myelogenous leukaemia | <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Treatment includes chemotherapy and/or bone marrow transplant. This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy. Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia. Acronym: AML Incidence: 2,000 new cases per year in the UK. Origin: Gr. Haima = blood (07 Apr 1998) |
| myelogenous | Referring to myelocytes, a type of white blood cell. Also called myeloid. (12 Dec 1998) |
| myelogenous leukemia |
a type of leukemia in which the cancer develops in the granulocytes or monocytes (myeloid cells).
Ãâó: www.uchicagokidshospital.org/online-library/conten...
|
|---|---|
| myelogenous leukemia |
Leukemia that develops in the myeloid cell lines.
Ãâó: www.leukine.com/patient/290.html
|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|